Study results: No adverse safety or virological changes 2 years following vorinostat

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy

A study conducted by Sharon Lewin did not reveal any long-term toxicity or changes in markers of HIV persistence or transcription in participants on ART who had received 14 days of vorinostat.

Read the full article here.

Share and Enjoy

  • Facebook
  • Twitter
  • Delicious
  • LinkedIn
  • StumbleUpon
  • Add to favorites
  • Email
  • RSS

Comments are closed.

Email
Print